Prostate Cancer Trial, Recruiting NCT07203482 Sponsor: NYU Langone Health Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07203482
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male and between the ages of 40 and 95
  • People who have prostate cancer that is contained within the prostate, confirmed by MRI scan and biopsy
  • People whose prostate cancer has not spread outside the prostate, and who have chosen a treatment called focal HIFU (a type of targeted ultrasound treatment) to treat their cancer
  • People whose cancer is at an early or low grade stage (known as Gleason 6 or 7)
  • People who are willing and able to give their informed consent to take part

Who may not be able to join:

  • People who have not been diagnosed with prostate cancer
  • People who have been diagnosed with prostate cancer that is contained within the prostate, but who have chosen a different treatment option other than focal HIFU
  • People who are unwilling or unable to give their consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: James Wysock, MD, NYU Langone Health

Phone: (646) 825-6338

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 May 2024
Est. completion
31 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Prostate-Specific Antigen (PSA) Levels; Change in Urinary Function Score; Change in Urinary Continence Score; Change in Sexual Function Score; Change in Ejaculatory Function Score; Change in Sexual Health Inventory for Men (SHIM) Score; Decision Regret Score; Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Imaging; Number of Participants with New Lesions in the Non-Treated Prostate on Post-Treatment Imaging; Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Prostate B...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov